Dm. Bloomfield et al., Comparison of spontaneous vs. metronome-guided breathing on assessment of vagal modulation using RR variability, AM J P-HEAR, 280(3), 2001, pp. H1145-H1150
Citations number
16
Categorie Soggetti
Cardiovascular & Hematology Research
Journal title
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
R-R interval variability (RR variability) is increasingly being used as an
index of autonomic activity. High-frequency (HF) power reflects vagal modul
ation of the sinus node. Since vagal modulation occurs at the respiratory f
requency, some investigators have suggested that HF power cannot be interpr
eted unless the breathing rate is controlled. We hypothesized that HF power
during spontaneous breathing would not differ significantly from HF power
during metronome-guided breathing. We measured HF power during spontaneous
breathing in 20 healthy subjects and 19 patients with heart disease. Each s
ubject's spontaneous breathing rate was determined, and the calculation of
HF power was repeated with a metronome set to his or her average spontaneou
s breathing rate. There was no significant difference between the logarithm
of HF power measured during spontaneous and metronome-guided breathing [4.
88 +/- 0.29 vs. 5.29 +/- 0.30 1n( ms(2)), P = 0.32] in the group as a whole
and when patients and healthy subjects were examined separately. We did ob
serve a small (9.9%) decrease in HF power with increasing metronome-guided
breathing rates (from 9 to 20 breaths/min). These data indicate that HF pow
er during spontaneous and metronome-guided breathing differs at most by ver
y small amounts. This variability is several logarithmic units less than th
e wide discrepancies observed between healthy subjects and cardiac patients
with a heterogeneous group of cardiovascular disorders. In addition, HF po
wer is relatively constant across the range of typical breathing rates. The
se data indicate that there is no need to control breathing rate to interpr
et HF power when RR variability (and specifically HF power) is used to iden
tify high-risk cardiac patients.